Tardive dyskinesia and atypical antipsychotic drugs

被引:89
作者
Casey, DE [1 ]
机构
[1] Vet Affairs Med Ctr, Div Mental Hlth, Portland, OR 97207 USA
关键词
atypical antipsychotics; clozapine; extrapyramidal symptoms; olanzapine; risperidone; tardive dyskinesia;
D O I
10.1016/S0920-9964(98)00160-1
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Typical antipsychotic agents produce central nervous system effects, especially extrapyramidal symptoms (EPS) and tardive dyskinesia (TD). Nearly every patient who receives neuroleptic therapy has one or more identifiable risk factors for TD, among the most significant of which are older age, female gender, presence of EPS, diabetes mellitus, affective disorders, and certain parameters of neuroleptic exposure (i.e. dose and duration of therapy). The typical course of TD is a gradual onset after several years of drug therapy, followed by slow improvement or remission, but a large number of patients have persistent TD with irreversible symptoms. In the management of TD, the patient's mental status is of primary concern. Currently, no uniformly safe and effective therapies for TD exist, though a variety of therapeutic agents, including some of the atypical neuroleptics, have been reported to treat TD successfully in some patients. Because TD liability is so much lower with novel antipsychotic therapy, all patients who have TD or are at risk for TD, as well as EPS, should be considered candidates for switching to these new drugs. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:S61 / S66
页数:6
相关论文
共 50 条
  • [1] Tardive Dyskinesia with Atypical Antipsychotic Drugs
    Ananth, Jambur
    Ananth, Kartik
    Keshavan, Aparna
    CURRENT DRUG THERAPY, 2007, 2 (03) : 168 - 176
  • [2] Atypical antipsychotic drugs and tardive dyskinesia:: relevance of D2 receptor affinity
    Bressan, RA
    Jones, HM
    Pilowsky, LS
    JOURNAL OF PSYCHOPHARMACOLOGY, 2004, 18 (01) : 124 - 127
  • [3] Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs
    Seigneurie, A. -S.
    Sauvanaud, F.
    Limosin, F.
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2016, 42 (03): : 248 - 254
  • [4] Tardive dyskinesia in children treated with atypical antipsychotic medications
    Wonodi, Ikwunga
    Reeves, Gloria
    Carmichael, Dana
    Verovsky, Ilene
    Avila, Matthew T.
    Elliott, Amie
    Hong, L. Elliot
    Adami, Helene M.
    Thaker, Gunvant K.
    MOVEMENT DISORDERS, 2007, 22 (12) : 1777 - 1782
  • [5] Atypical Antipsychotic-Induced Tardive Dyskinesia in a Middle-Aged Schizophrenic Patient: A Case Report
    Mulla, Walaa E.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [6] Atypical Antipsychotic Adjustments and Side-Effects over Time in Adults with Intellectual Disability, Tardive Dyskinesia, and Akathisia
    Matson, Johnny L.
    Rivet, Tessa T.
    Fodstad, Jill C.
    JOURNAL OF DEVELOPMENTAL AND PHYSICAL DISABILITIES, 2010, 22 (05) : 447 - 461
  • [7] Incidence of Tardive Dyskinesia With Atypical Versus Conventional Antipsychotic Medications: A Prospective Cohort Study
    Woods, Scott W.
    Morgenstern, Hal
    Saksa, John R.
    Walsh, Barbara C.
    Sullivan, Michelle C.
    Money, Roy
    Hawkins, Keith A.
    Gueorguieva, Ralitza V.
    Glazer, William M.
    JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (04) : 463 - 474
  • [8] Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature
    Peritogiannis, V.
    Tsouli, S.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2010, 24 (07) : 1121 - 1125
  • [9] Antipsychotic-induced tardive dyskinesia: update on epidemiology and management
    Widschwendter, Christian G.
    Hofer, Alex
    CURRENT OPINION IN PSYCHIATRY, 2019, 32 (03) : 179 - 184
  • [10] Pathophysiological mechanisms underlying antipsychotic-induced tardive dyskinesia
    Vayman, E. E.
    Shnayder, N. A.
    Neznanov, N. G.
    Nasyrova, R. F.
    BYULLETEN SIBIRSKOY MEDITSINY, 2019, 18 (04): : 169 - 184